Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Accumulated Expenses (2023 - 2026)

MBX Biosciences has reported Accumulated Expenses over the past 4 years, most recently at $7.4 million for Q1 2026.

  • Quarterly results put Accumulated Expenses at $7.4 million for Q1 2026, up 504.32% from a year ago — trailing twelve months through Mar 2026 was $7.4 million (up 504.32% YoY), and the annual figure for FY2025 was $12.3 million, up 431.24%.
  • Accumulated Expenses reached $7.4 million in Q1 2026 per MBX's latest filing, down from $12.3 million in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $12.3 million in Q4 2025 and bottomed at $1.2 million in Q1 2025.
  • Median Accumulated Expenses over the past 4 years was $4.3 million (2024), compared with a mean of $4.9 million.
  • The largest annual shift saw Accumulated Expenses tumbled 51.7% in 2025 before it soared 504.32% in 2026.
  • Over 4 years, Accumulated Expenses stood at $1.4 million in 2023, then soared by 70.26% to $2.3 million in 2024, then surged by 431.24% to $12.3 million in 2025, then crashed by 39.94% to $7.4 million in 2026.
  • Business Quant data shows Accumulated Expenses for MBX at $7.4 million in Q1 2026, $12.3 million in Q4 2025, and $2.8 million in Q3 2025.